MCM
BPMC

Marathon Capital Management’s Blueprint Medicines BPMC Stock Holding History

Marathon Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,839
Closed -$292K – 176
2021
Q3 		$292K Buy
+2,839
New +$264K 0.07% 161

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marathon Capital Management's BPMC Position: Q4 2021 in Review

Marathon Capital Management sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 2,839 shares — an estimated $292K sold.

Marathon Capital Management first reported a position in BPMC in Q3 2021 and held it in 1 quarter. The position peaked at $292K in Q3 2021. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • Marathon Capital Management reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • Marathon Capital Management sold 2,839 Blueprint Medicines shares in Q4 2021, an estimated $292K.
  • Marathon Capital Management first reported a position in Blueprint Medicines in Q3 2021 and held it in 1 quarter.
  • Marathon Capital Management's Blueprint Medicines position peaked at $292K in Q3 2021.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on Marathon Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.